AR-709与其他药物相比的抗链球菌活性。
Antistreptococcal activity of AR-709 compared to that of other agents.
作者信息
Smith Kathy, Ednie Lois M, Appelbaum Peter C, Hawser Stephen, Lociuro Sergio
机构信息
Department of Pathology, Hershey Medical Center, Hershey, PA 17033, USA.
出版信息
Antimicrob Agents Chemother. 2008 Jun;52(6):2279-82. doi: 10.1128/AAC.01620-07. Epub 2008 Mar 24.
Abstract
Against 300 strains of pneumococci and 100 group A streptococci of differing beta-lactam, macrolide, and quinolone resistance phenotypes, AR-709 was very active, with all MICs being < or =2 microg/ml. Furthermore, AR-709 was active against strains that were both susceptible and resistant to trimethoprim-sulfamethoxazole.
摘要
针对300株肺炎球菌和100株具有不同β-内酰胺、大环内酯和喹诺酮耐药表型的A组链球菌，AR-709活性很强，所有最低抑菌浓度均≤2微克/毫升。此外，AR-709对甲氧苄啶-磺胺甲恶唑敏感和耐药的菌株均有活性。
相似文献
1
Antistreptococcal activity of AR-709 compared to that of other agents.
Antimicrob Agents Chemother. 2008 Jun;52(6):2279-82. doi: 10.1128/AAC.01620-07. Epub 2008 Mar 24.
2
Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America.
Antimicrob Agents Chemother. 2008 Mar;52(3):1147-9. doi: 10.1128/AAC.01387-07. Epub 2008 Jan 7.
3
Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 1997 Nov;41(11):2406-13. doi: 10.1128/AAC.41.11.2406.
4
Comparison of antimicrobial in vitro activities against Streptococcus pneumoniae independent of MIC susceptibility breakpoints using MIC frequency distribution curves, scattergrams and linear regression analyses.
J Antimicrob Chemother. 2001 Nov;48(5):609-15. doi: 10.1093/jac/48.5.609.
5
In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2009 Apr;53(4):1690-2. doi: 10.1128/AAC.01388-08. Epub 2009 Jan 12.
6
In vitro synergism between rokitamycin and co-trimoxazole against Streptococcus pyogenes, Streptococcus pneumoniae and staphylococci.
Int J Antimicrob Agents. 2008 Feb;31(2):185-7. doi: 10.1016/j.ijantimicag.2007.10.012. Epub 2007 Dec 21.
7
Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.
Antimicrob Agents Chemother. 2001 Nov;45(11):3242-5. doi: 10.1128/AAC.45.11.3242-3245.2001.
8
In vitro activity of AR-709 against Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2008 Mar;52(3):1182-3. doi: 10.1128/AAC.01332-07. Epub 2008 Jan 7.
9
Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes.
J Antimicrob Chemother. 2005 Dec;56(6):1130-3. doi: 10.1093/jac/dki361. Epub 2005 Oct 20.
10
Factors that cause trimethoprim resistance in Streptococcus pyogenes.
Antimicrob Agents Chemother. 2014;58(4):2281-8. doi: 10.1128/AAC.02282-13. Epub 2014 Feb 3.
引用本文的文献
1
Inhibitor design to target a unique feature in the folate pocket of Staphylococcus aureus dihydrofolate reductase.
Eur J Med Chem. 2020 Aug 15;200:112412. doi: 10.1016/j.ejmech.2020.112412. Epub 2020 May 20.
2
Modified 2,4-diaminopyrimidine-based dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis.
Bioorg Med Chem. 2015 Jan 1;23(1):203-11. doi: 10.1016/j.bmc.2014.11.009. Epub 2014 Nov 11.
3
A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung.
Eur J Clin Pharmacol. 2013 Sep;69(9):1673-82. doi: 10.1007/s00228-013-1528-2. Epub 2013 Jun 6.
4
Structure-activity relationship for enantiomers of potent inhibitors of B. anthracis dihydrofolate reductase.
Biochim Biophys Acta. 2013 Jan;1834(1):46-52. doi: 10.1016/j.bbapap.2012.09.001. Epub 2012 Sep 20.
5
Synthesis and biological activity of substituted 2,4-diaminopyrimidines that inhibit Bacillus anthracis.
Eur J Med Chem. 2012 Aug;54:387-96. doi: 10.1016/j.ejmech.2012.05.018. Epub 2012 May 22.
本文引用的文献
1
In vitro activity of AR-709 against Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2008 Mar;52(3):1182-3. doi: 10.1128/AAC.01332-07. Epub 2008 Jan 7.
2
Activity of the Diaminopyrimidine AR-709 against recently collected multidrug-resistant isolates of invasive Streptococcus pneumoniae from North America.
Antimicrob Agents Chemother. 2008 Mar;52(3):1147-9. doi: 10.1128/AAC.01387-07. Epub 2008 Jan 7.
3
Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.
JAMA. 2007 Oct 17;298(15):1772-8. doi: 10.1001/jama.298.15.1772.
4
Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis.
Clin Microbiol Infect. 2003 Sep;9(9):966-9. doi: 10.1046/j.1469-0691.2003.00670.x.
5
Antibacterial resistance in Streptococcus pneumoniae and Haemophilus influenzae from Italy and Spain: data from the PROTEKT surveillance study, 1999-2000.
J Chemother. 2003 Jun;15(3):226-34. doi: 10.1179/joc.2003.15.3.226.
6
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
J Antimicrob Chemother. 2003 Aug;52(2):229-46. doi: 10.1093/jac/dkg321. Epub 2003 Jul 15.
7
Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study.
Diagn Microbiol Infect Dis. 2003 Apr;45(4):251-9. doi: 10.1016/s0732-8893(02)00522-9.
8
Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain.
Antimicrob Agents Chemother. 2001 Dec;45(12):3334-40. doi: 10.1128/AAC.45.12.3334-3340.2001.
9
Antipneumococcal activity of ABT-773 compared to those of 10 other agents.
Antimicrob Agents Chemother. 2000 Jul;44(7):1894-9. doi: 10.1128/AAC.44.7.1894-1899.2000.
10
Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis.
J Antimicrob Chemother. 2000 May;45(5):623-31. doi: 10.1093/jac/45.5.623.
Zotero 插件